{"prompt": "['MC1752', '54', 'Pregnancy.', \"Unacceptable toxicity that in the treating provider's discretion places the patient at risk for\", 'future significant harm.', 'Intercurrent illness that prevents continuation of therapy or follow up.', 'Protocol Version Date: 21JUN2018']['MC1752', '55', '14.0', 'Body Fluid Biospecimens', '14.1', 'Collection and Processing', '14.11 Optional research specimen(s) collection per protocol IRB 16-005260 will be', 'done after consenting for 16-005260 and according to that protocol. All', 'collection time points and processing will be done per that protocol. Data from', 'IRB 16-005260 may be used for this study after IRB approval.', '15.0', 'Drug Information', '15.1', 'Avelumab (Bavencio)', '15.11', 'Background: Avelumab is a fully human IgG1 antibody directed against PD-L1.', 'Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its', 'receptors PD-1 and B7.1. This removes the suppressive effects of PD-L1 on anti-', 'tumor CD8+ T cells, resulting in the restoration of cytotoxic T cell response.', '15.12', 'Formulation: Avelumab is a sterile, clear, and colorless concentrate for solution', 'available in a concentration of 20 mg/mL. Each single-use vial contains 200', 'mg of avelumab as a preservative-free acetate-buffered solution (pH 5.2)', 'containing Mannitol, and Polysorbate 20 (Tween 20).', '15.13', 'Preparation and storage: Allow each vial to equilibrate to room temperature.', 'Avelumab drug product must be diluted in 250 mL of 0.9% saline solution', '(sodium chloride injection) supplied in an infusion bag; alternatively a 0.45%', 'saline solution can be used if needed. Use a disposable syringe equipped with a', 'needle of suitable size to remove a volume of sodium chloride solution to be', 'replaced by avelumab from the infusion bag and discard the removed solution.', 'Use a new disposable syringe equipped with a needle of suitable size to inject a', 'volume of avelumab drug product identical to the discarded volume of sodium', 'chloride solution into the infusion bag. Gently invert the mixture 10 times.', 'Infusion bags must not be shaken, in order to avoid foaming or excessive', 'shearing of the protein solution. The preparation must be carefully inspected as it', 'should result in a homogeneous looking clear solution, free of visible particles.', 'No other drugs should be added to the solution for infusion containing avelumab.', 'Avelumab drug product must be stored at 2\u00b0C to 8\u00b0C until use. If not used', 'immediately, the diluted drug product can be stored up to 8 hours at room', 'temperature or up to 24 hours at 2\u00b0C to 8\u00b0C. Avelumab drug product must not be', 'frozen.', '15.14 Administration: Avelumab is administered as a 1-hour IV infusion. Administer', 'the diluted solution through an intravenous line containing a sterile, non-', 'pyrogenic, low protein binding in-line filter (pore size of 0.2 micron).', '15.15 Pharmacokinetic information:', 'Absorption: Avelumab is administered intravenously and is 100%', 'bioavailable. Steady-state concentrations of avelumab are expected to be', 'Protocol Version Date: 21JUN2018']['MC1752', '56', 'reached by the 3rd dosing cycle (10 mg/kg dose every 2 weeks), and the', 'accumulation ration is 1.25.', 'Distribution: The geometric mean volume of distribution at steady state for a', 'subject receiving 10 mg/kg was 4.72 L.', 'Metabolism: Avelumab is degraded by proteolytic catabolism. CYP450 does', 'not contribute to its metabolism.', 'Elimination: The primary elimination mechanism of avelumab is proteolytic', 'degradation. Based on population pharmacokinetic analyses in patients with solid', 'tumors, the total systemic clearance was 0.59 L/day. The terminal half-life was', '6.1 days in patients receiving 10 mg/kg every 2 weeks.', '15.16', 'Potential Drug Interactions: Avelumab is not expected to have drug-drug', 'interactions with other drugs because it is primarily metabolized through', 'catabolic pathways and is not expected to affect the expression of CYP450', 'enzymes.', '15.17 Known potential toxicities: Consult the package insert for the most current and', 'complete information.', 'Very Common @> 10%): Anemia, nausea, diarrhea, vomiting, abdominal pain,', 'fatigue, pyrexia, peripheral edema, infusion related reaction, weight decreased,', 'decreased appetite, back pain, arthralgia, cough, dyspnea', 'Common ( 1% - < 10%): Hypothyroidism, chills, pneumonitis, rash, pruritus,', 'rash maculopapular', 'Uncommon @> 0.1% - < 1%): Adrenal insufficiency, hyperthyroidism,', 'thyroiditis, autoimmune thyroiditis, adrenocortical insufficiency acute,', 'hypopituitarism, uveitis, colitis, autoimmune colitis, enterocolitis, autoimmune', 'hepatitis, acute hepatic failure, hepatic failure, hepatitis, drug hypersensitivity,', 'anaphylactic reaction, aspartate aminotransferase (AST) increased, alanine', 'aminotransferase (ALT) increased, blood creatine phosphokinase increased,', 'transaminases increased, diabetes mellitus, myositis, Guillian-Barr\u00e9 syndrome,', 'tubulointerstitial nephritis, rash pruritic, erythema, rash generalized, rash', 'erythematous, rash macular, rash papular, dermatitis exfoliative, erythema', 'multiforme, pemphigoid, pruritis generalized.', 'Adverse reactions with observed fatal outcome in the avelumab clinical', 'development programs included: immune-related pneumonitis, immune-related', 'hepatitis, and immune-related myocarditis.', '15.18 Drug procurement:', 'Investigational avelumab is provided free of charge to patients by EMD', 'Serono a subsidiary of Merk KGaA. Outdated or remaining drug is to', 'be destroyed on-site per procedures and local regulations in place at each', 'institution.', '15.19', 'Nursing Guidelines:', '15.191 Avelumab side effects vary greatly from those of traditional', 'chemotherapy and can vary in severity from mild to life threatening.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}